Active, not recruitingPhase 2NCT05507541
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Studying ALK-positive large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Stephen M. Ansell, MD, PhD, M.DMayo Clinic in Rochester
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (2)
- University of Iowa, Iowa City, Iowa, United States
- Mayo Clinic, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05507541 on ClinicalTrials.govOther trials for ALK-positive large B-cell lymphoma
Additional recruiting or active studies for the same condition.